| ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About | |
Efficacy/safety of ecraprost in lipid emulsion for treatment of critical leg ischemia due to peripheral arterial disease
This study is currently recruiting patients.
| Sponsored by: | Mitsubishi Pharma Corporation |
|---|---|
| Information provided by: | Mitsubishi Pharma Corporation |
Purpose
Ecraprost in lipid emulsion is being developed for the treatment of Critical leg ischemia (CLI), which is the most severe form of peripheral arterial disease(PAD);This trial is designed to assess the efficacy and safety of the drug in the treatment of CLI.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Critical Limb Ischemia due to peripheral arterial disease |
Drug: Ecraprost in lipid emulsion |
Phase III |
MedlinePlus consumer health information
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A double-blind, randomized, placebo-controlled study to assess the efficacy and safety of CirculaseTM in conjunction with peripheral revascularization for the treatment of critical leg ischemia
Expected Total Enrollment: 280
Study start: August 2001;
Study completion: May 2004
Eligibility
Ages Eligible for Study: 40 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
Exclusion Criteria:
Location
and Contact
Information
More Information
 | ||||||||||||||
| U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
| National Institutes of Health, Department of Health & Human Services | ||||||||||||||
| Copyright, Privacy, Accessibility, Freedom of Information Act | ||||||||||||||